膀胱癌中VISTA和PD-1/PD-L1表达与免疫抑制微环境和肿瘤进展的相关性研究

doi:10.3969/j.issn.1009-976X.2023.02.007

摘要/Abstract

摘要： 目的应用公共数据库和我院样本初步分析鉴定膀胱癌中高表达T细胞激活抑制物免疫球蛋白可变区结构域（VISTA）与细胞程序性死亡受体-1（PD-1）/PD-1配体（PD-L1）的肿瘤微环境组成特征,并在小鼠皮下膀胱癌模型上测试联合阻断VISTA与PD-1的抗肿瘤效力。方法利用TCGA膀胱癌数据库,通过差异分析筛选高表达VISTA与PD-1/PD-L1病人对比低表达病人的差异基因,通过GO通路富集分析筛选差异富集的通路;通过cibersort分析高/低表达VISTA与PD-1/PD-L1膀胱癌的免疫浸润特征并利用我院样本进行蛋白水平验证;分析我院膀胱癌病人高/低表达VISTA和PD-1/PD-L1与其临床病理特征的相关性。建立小鼠的皮下膀胱癌模型,联合应用抗VISTA抗体以及抗PD-1抗体,监测肿瘤生长以探究其抗肿瘤效力。结果 TCGA数据库中,VISTA在膀胱癌中高表达与多种免疫抑制性通路相关,与M2型巨噬细胞、CD8⁺ T细胞相关,与CD163、MRC1等免疫抑制分子相关;VISTA还与PD-1、PD-L1等多种负性免疫检查点相关;同时高表达VISTA和PD-1/PD-L1与M1型巨噬细胞、CD8⁺ T细胞相关,与CD163、MRC1等免疫抑制分子相关。我院膀胱癌队列中,VISTA表达与PD-1、PD-L1相关;免疫细胞上同时高表达VISTA和PD-1/PD-L1与更高的T分期、组织学分级以及CD8⁺ T细胞浸润数量相关。小鼠的皮下膀胱癌模型中联合应用抗VISTA抗体以及抗PD-1抗体更能抑制肿瘤生长。结论本研究结合TCGA膀胱癌数据库和我院膀胱癌队列分析发现,VISTA在膀胱癌中高表达与免疫抑制微环境相关;膀胱癌中同时高表达VISTA和PD-1/PD-L1呈现出不一样的免疫微环境特征且与恶性肿瘤特征相关。联合阻断VISTA以及PD-1显示更加强大的抗肿瘤效力。这些结果为联合阻断VISTA和PD-1/PD-L1免疫疗法在膀胱癌中的应用提供了理论依据。

关键词: 膀胱癌, VISTA, PD-1/PD-L1, 免疫抑制微环境, 联合治疗

Abstract: Objective The aim of this article was to preliminarily identify the components of tumor microenvironment （TME） characterized by high expression of V-domain immunoglobulin suppressor of T-cell activation（VISTA） and/or Programmed cell Death-1 （PD-1）/PD-1 Ligand （PD-L1） utilizing the public databases and our cohort, and test the efficacy of combination therapy of VISTA blockade and PD-1 blockade in mouse subcutaneous urothelial carcinoma of bladder （UCB） model. Methods We utilized TCGA-UCB dataset to screen out differentially expressing genes （DEGs） in tumors with high expression of VISTA and/or PD-1/PD-L1. The differentially enriched pathways were confirmed by GO （Gene Ontology） pathway enrichment analysis. Immune cell composition of the TME with high/low expression of VISTA and/or PD-1/PD-L1 was evaluated by cibersort analysis, which was verified on a protein level using our own cohort. The associations of high expression of VISTA and/or PD-1/PD-L1 with clinicopathological characteristics were accessed in our cohort. We established subcutaneous mouse UCB model and tested the anti-tumor efficacy of VISTA blockade plus PD-1 blockade by monitoring the tumor growth. Results In TCGA-UCB dataset, high expression of VISTA was associated with multiple immunoinhibitory pathways, increased infiltration of M2 macrophages and CD8⁺ T cells and immunosuppressive molecules such as CD163 and MRC1. VISTA was positively associated with multiple immunosuppressive immune checkpoints including PD-1 and PD-L1. Simultaneous high expression of VISTA and PD-1/PD-L1 was associated with M1 macrophage and CD8⁺ T cell infiltration and immunoinhibitory molecules such as CD163 and MRC1. In our own UCB cohort, VISTA was also positively associated with PD-1/PD-L1 expression. Simultaneous high expression of VISTA and PD-1/PD-L1 was associated with higher T stage, histological grade and CD8⁺ T cell infiltration. Combination of VISTA and PD-1 blockade in subcutaneous mouse UCB model showed greater inhibition of tumor growth. Conclusion In this study, we used TCGA-UCB dataset and our own UCB cohort and found that high expression of VISTA was associated with immunosuppressive TME. Simultaneous high expression of VISTA and PD-1/PD-L1 presented different TME features and associated with advanced clinicopathological characteristics of UCB patients. VISTA blockade plus PD-1 blockade exhibited stronger anti-tumor efficacy. These findings provided theoretical support for the application of combination of VISTA and PD-1 blockade in UCB immunotherapy.

Key words: bladder cancer, VISTA, PD-1/PD-L1, immunosuppressive TME, combination therapy

中图分类号:

R737.14

欧子维, 王博, 钟文龙, 黄健. 膀胱癌中VISTA和PD-1/PD-L1表达与免疫抑制微环境和肿瘤进展的相关性研究[J]. 岭南现代临床外科, 2023, 23(02): 135-144.

OU Zi-wei, WANG Bo, ZHONG Wen-long, HUANG Jian. The associations of VISTA and PD-1/PD-L1 expression in UCB with immunosuppressive TME and tumor progression[J]. Lingnan Modern Clinics In Surgery, 2023, 23(02): 135-144.

参考文献

[1] 黄健. 中国泌尿外科和男科疾病诊断治疗指南. 北京: 科学出版社; 2020:59-61.
[2] Lenis AT, Lec PM, Chamie K, Mshs MD.Bladder Cancer: A Review[J]. JAMA, 2020, 324(19): 1980-1991.
[3] Darvin P, Toor SM, Sasidharan Nair V, Elkord E.Immune checkpoint inhibitors: recent progress and potential biomarkers[J]. Exp Mol Med, 2018, 50(12): 1-11.
[4] Yuan L, Tatineni J, Mahoney KM, Freeman GJ.VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy[J]. Trends Immunol, 2021, 42(3): 209-227.
[5] Wang L, Rubinstein R, Lines JL, et al.VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses[J]. J Exp Med, 2011, 208(3): 577-592.
[6] Lines JL, Sempere LF, Broughton T, et al.VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy[J]. Cancer Immunol Res, 2014, 2(6): 510-517.
[7] Liu J, Xie X, Xuan C, et al.High-Density Infiltration of V-domain Immunoglobulin Suppressor of T-cell Activation Up-regulated Immune Cells in Human Pancreatic Cancer[J]. Pancreas, 2018, 47(6): 725-731.
[8] Blando J, Sharma A, Higa MG, et al.Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer[J]. Proc Natl Acad Sci U S A, 2019, 116(5): 1692-1697.
[9] Flies DB, Han X, Higuchi T, et al.Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity[J]. J Clin Invest, 2014, 124(5): 1966-1975.
[10] Deng J, Li J, Sarde A, et al.Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment[J]. Cancer Immunol Res, 2019, 7(7): 1079-1090.
[11] Liu J, Yuan Y, Chen W, et al.Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses[J]. Proc Natl Acad Sci U S A, 2015, 112(21): 6682-6687.
[12] Schaafsma E, Croteau W, ElTanbouly M, et al. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance[J]. Cancer Immunol Res, 2023, 11(1): 38-55.
[13] Wang B, Pan W, Yang M, et al.Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder[J]. Cancer Sci, 2019, 110(2): 489-498.
[14] Hosseinkhani N, Derakhshani A, Shadbad MA, et al.The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead[J]. Front Immunol, 2021, 12: 676181.
[15] Villarroel-Espindola F, Yu X, Datar I, et al.Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer[J]. Clin Cancer Res, 2018, 24(7): 1562-1573.
[16] He HX, Gao Y, Fu JC, et al.VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma[J]. Oncoimmunology, 2021, 10(1): 1907059.
[17] Le Mercier I, Chen W, Lines JL, et al.VISTA Regulates the Development of Protective Antitumor Immunity[J]. Cancer Res, 2014, 74(7): 1933-1944.
[18] Wang J, Wu H, Chen Y, et al.B7-H5 blockade enhances CD8(+) T-cell-mediated antitumor immunity in colorectal cancer[J]. Cell Death Discov, 2021, 7(1): 248.
[19] Boger C, Behrens HM, Kruger S, Rocken C.The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?[J]. Oncoimmunology, 2017, 6(4): e1293215.
[20] Zong L, Zhou Y, Zhang M, et al.VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer[J]. Cancer Immunol Immunother, 2020, 69(1): 33-42.
[21] Takeuchi O, Akira S.Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6): 805-820.
[22] Berzofsky JA. Improving immunotherapy: revisiting the immunologist′s little secret [J]. Sci Transl Med, 2012, 4(120): 120fs124.
[23] Xu W, Dong J, Zheng Y, et al.Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression[J]. Cancer Immunol Res, 2019, 7(9): 1497-1510.
[24] Babjuk M, Bohle A, Burger M, et al.EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016[J]. Eur Urol, 2017, 71(3): 447-461.
[25] Redelman-Sidi G, Glickman MS, Bochner BH.The mechanism of action of BCG therapy for bladder cancer--a current perspective[J]. Nat Rev Urol, 2014, 11(3): 153-162.
[26] von Meyenn F, Schaefer M, Weighardt H, et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells[J]. Immunobiology, 2006, 211(6-8): 557-565.